• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

    4/29/25 8:35:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBRX alert in real time by email

    Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025



    Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line therapies both in vitro and in vivo

    HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that an abstract and poster presentation regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 28, 2025, at the McCormick Place Convention Center in Chicago, IL.

    "The case for expanding the potential markets for Annamycin continues to get stronger," said Walter Klemp, Chairman and CEO of Moleculin. "In an environment where more and more cancer treatment regimens are combinations of two or more drugs, it is encouraging to see that Annamycin appears capable of generating synergistic results with so many commonly used drugs. The latest research continues to support our view that, in addition to hematological malignancies, solid cancers including sarcoma and pancreatic cancer also represent important expansion opportunities for Annamycin. These findings may help expand the clinical use of Annamycin and consequently make our drug candidate even more attractive to prospective future partners. With five previous or current investigator-initiated clinical trials supporting development of our drug candidates, we believe that our next investigator-initiated trials could be Annamycin for the treatment of pancreatic cancer or advance soft tissue sarcomas."

    The study, presented in poster form, was designed to assess the efficacy of Annamycin in combination with approved anticancer agents in order to identify novel potentially highly efficacious clinical applications of Annamycin alone and with a therapeutic partner. Annamycin in its non-liposomal form (free drug; in vitro) and Liposomal Annamycin (L-ANN; in vivo) were tested in combination with selected US Food and Drug Administration (FDA) approved drugs. Usually, the most efficacious drug combinations from the in vitro studies were then tested using well developed in vivo models of leukemia and solid tumors, including sarcoma and pancreatic cancer.

    It should be noted that in a separate set of previous experiments, Annamycin activity was tested in vitro, and appeared to be highly active, against drug resistant cell lines, including cells resistant to cytarabine and venetoclax.

    The research shown in the AACR poster, described below, demonstrates that Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer agents both in vitro and in vivo. Ongoing studies are working towards identifying new efficacious clinical applications of L-ANN drug combinations with the long-term goal of developing novel therapeutic strategies for treatment resistant cancers.

    Details of the poster presentation are as follows:

    Title: Combining Annamycin, a Non-cardiotoxic Potent Topo II Poison, with Azacitidine, Cytarabine, Gemcitabine, Ifosfamide, Trabectedin, or Vincristine to Synergize Anticancer Effects and Identify Potential Clinical Applications

    Track: Experimental and Molecular Therapeutics

    Session: PO.ET02.03. Drug Combination Strategies for Cancer Treatment

    Abstract Number: 1683/ 14

    Presenter: Waldemar Priebe, Ph.D., Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center



    For more information, visit the AACR Annual Meeting website.

    About Moleculin Biotech, Inc.

    Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.



    The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.



    Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

    For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

    Forward-Looking Statements



    Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Annamycin to demonstrate in clinical trials the results from the animal models described in the poster. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,' ‘estimates,' ‘anticipates,' ‘expects,' ‘plans,' ‘projects,' ‘intends,' ‘potential,' ‘may,' ‘could,' ‘might,' ‘will,' ‘should,' ‘approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

    Investor Contact:

    JTC Team, LLC

    Jenene Thomas

    (908) 824-0775

    [email protected]



    Primary Logo

    Get the next $MBRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBRX

    DatePrice TargetRatingAnalyst
    2/12/2025Buy → Hold
    Maxim Group
    7/18/2022$14.00Outperform
    Oppenheimer
    More analyst ratings

    $MBRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML  Regulatory and site selection progress to date supports interim data readout expected in the second half of 2025 Recently received European Medicines Agency (EMA) approval adds nine additional countries to the Company's ongoing MIRACLE trial; Authorization granted in all EU countries requested Company to host conference call and webcast today, May 14th at 8:30 AM ET HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug

      5/14/25 7:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

      Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin for the treatment of R/R AML; Interim data readout expected in the second half of 2025 Subjects targeted for the "MIRACLE" trial include venetoclax regimen failures where outcomes with currently available therapies are considered dismal HOUSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and

      5/12/25 8:40:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

      HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

      5/7/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

      Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON, Nov. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the appointment of Daniel D. Von Hoff, M.D., F.A.C.P., FASCO, FAACR to its Annamycin Scientific Advisory Board. Walter Klemp, Chairman and Chief Executive Officer of Moleculin commented, "We are very pleased to welco

      11/4/24 8:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

      Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Company's AML clinical development program as well as data demonstrated to dateOngoing development progress of Annamycin toward pivotal AML study in 2024 with potential qualification for an accelerated approval pathwayHOUSTON, May 2, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will host a virtual AML Clinica

      5/2/24 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

      –     Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman. Dr. Tallman is an internationally renowned clinical investigator whose discoveries have fueled the progress of leukemia-

      5/1/24 8:50:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Financials

    Live finance-specific insights

    See more

    $MBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML  Regulatory and site selection progress to date supports interim data readout expected in the second half of 2025 Recently received European Medicines Agency (EMA) approval adds nine additional countries to the Company's ongoing MIRACLE trial; Authorization granted in all EU countries requested Company to host conference call and webcast today, May 14th at 8:30 AM ET HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug

      5/14/25 7:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

      HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

      5/7/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

      – Continued progress in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) toward first subject treated, on track to take place in the first quarter of 2025 – Multiple subjects currently being screened in first MIRACLE site activated – Initial data readout of the Phase 3 MIRACLE trial expected in the second half of 2025 – Company to host conference call and webcast today, Monday, March 24th at 8:30 AM ET HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported its financial results

      3/24/25 7:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Foster Jonathan P. bought $20,000 worth of shares (28,986 units at $0.69), increasing direct ownership by 56% to 80,556 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:32:37 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • George Robert E. bought $10,000 worth of shares (14,493 units at $0.69), increasing direct ownership by 8,678% to 14,660 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:31:57 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Klemp Walter V bought $129,999 worth of shares (188,404 units at $0.69), increasing direct ownership by 38% to 680,880 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:31:05 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

      SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      11/14/24 5:12:06 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Moleculin Biotech Inc.

      SC 13G - Moleculin Biotech, Inc. (0001659617) (Subject)

      2/14/24 3:43:13 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      2/10/21 11:28:21 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Moleculin Biotech Inc.

      SCHEDULE 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      5/15/25 3:30:38 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/14/25 7:30:28 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Moleculin Biotech Inc.

      10-Q - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/13/25 4:15:56 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yan Joy

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:06:10 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cermak Elizabeth

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:05:23 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Climaco John M

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:04:49 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Moleculin Biotech downgraded by Maxim Group

      Maxim Group downgraded Moleculin Biotech from Buy to Hold

      2/12/25 8:44:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Moleculin Biotech with a new price target

      Oppenheimer resumed coverage of Moleculin Biotech with a rating of Outperform and set a new price target of $14.00

      7/18/22 9:16:10 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital resumed coverage on Moleculin Biotech

      Roth Capital resumed coverage of Moleculin Biotech with a rating of Buy

      2/1/21 4:03:54 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care